慢性腎臓病治療薬の世界市場:疫学予測

◆英語タイトル:Chronic Kidney Disease - Epidemiology Forecast to 2030
◆商品コード:DELV20JU184
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年5月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(184名様閲覧)USD3,750 ⇒換算¥393,750見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥590,625見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Chronic kidney disease (CKD)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Chronic kidney disease in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2017-2030

Chronic Kidney Disease Understanding
Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney function over a period of months to years. The initial symptoms include leg swelling, feeling tired, vomiting, loss of appetite, and confusion; complications in CKD involve anemia, bine disease, high blood pressure and increased risk of heart disease. Anemia is common and is especially prevalent in those requiring hemodialysis. It is multifactorial in cause, but includes increased inflammation, reduction in erythropoietin, and hyperuricemia leading to bone marrow suppression.

Chronic Kidney Disease Epidemiology Perspective by DelveInsight
The Chronic kidney disease (CKD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Chronic kidney disease are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Chronic Kidney Disease Detailed Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Diagnosed Prevalent cases of CKD, Prevalent cases of CKD by stage, Prevalent cases of CKD by etiologies, Comorbidities associated with CKD, Dialysis dependency in CKD) scenario of Chronic kidney disease (CKD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period,along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of prevalent cases of Chronic kidney disease (CKD) in 7 MM was found to be 122,704,658 in the year 2017.

Scope of the Report
The report covers detailed overview of Chronic kidney disease explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
The report provides the insight about the historical and forecasted patient pool of Chronic kidney disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
The Report assesses the disease risk and burden and highlights the unmet needs of the disease
The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
The report provides the segmentation of the disease epidemiology by Diagnosed Prevalent cases of CKD, Prevalent cases of CKD by stage, Prevalent cases of CKD by etiologies, Comorbidities associated with CKD, Dialysis dependency in CKD in 7MM

Report Highlights
11 Years Forecast
7MM Coverage
Epidemiology Segmentation
Key Cross Competition
Market Size by Therapies
Drugs Uptake

Key Assessments
Pipeline Product Profiles
Key Products and Key Players
Market Drivers and Barriers

【レポートの目次】

1. Key Insights

2. Executive Summary of Chronic Kidney Disease

3. SWOT Analysis for Chronic Kidney Disease

4. Chronic Kidney Disease (CKD) Market Overview at a Glance

4.1. Market Share (%) Distribution of Chronic Kidney Disease (CKD) in 2017

4.2. Market Share (%) Distribution of Chronic Kidney Disease (CKD) in 2030

5. Disease Background and Overview

5.1. Introduction

5.2. The KDIGO classification of CKD

5.3. Risk factors associated with CKD

5.4. Signs and symptoms

5.5. Pathophysiology

. Complications

5.6. Disease Progression

5.7. Diagnosis, Screening and Prevention

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Patient Population of Chronic Kidney Disease (CKD)

. Country Wise-Epidemiology of CKD

6.3. The United States

6.3.1. Assumptions and Rationale

6.3.2. Diagnosed Prevalent cases of CKD

6.3.3. Prevalent cases of CKD by stage

6.3.4. Prevalent cases of CKD by etiologies in the United States

6.3.5. Comorbidities associated with CKD in the United States

6.3.6. Dialysis Dependency in CKD

6.4. EU-5

6.4.1. Assumptions and Rationale

6.4.2. Germany

6.4.2.1. Diagnosed Prevalent cases of CKD in Germany

6.4.2.2. Prevalent cases of CKD by stage in Germany

6.4.2.3. Prevalent cases of CKD by etiologies in Germany

6.4.2.4. Comorbidities associated with CKD in Germany

6.4.2.5. Dialysis Dependency in CKD in Germany

6.4.3. France

6.4.3.1. Diagnosed Prevalent cases of CKD in France

6.4.3.2. Prevalent cases of CKD by stage in France

6.4.3.3. Prevalent cases of CKD by etiologies in France

6.4.3.4. Comorbidities associated with CKD in France

6.4.3.5. Dialysis Dependency in CKD in France

6.4.4. Italy

6.4.4.1. Diagnosed Prevalent cases of CKD in Italy

6.4.4.2. Prevalent cases of CKD by stage in Italy

6.4.4.3. Prevalent cases of CKD by etiologies in Italy

6.4.4.4. Comorbidities associated with CKD in Italy

6.4.4.5. Dialysis Dependency in CKD in Italy

6.4.5. Spain

6.4.5.1. Diagnosed Prevalent cases of CKD in Spain

6.4.5.2. Prevalent cases of CKD by stage in Spain

6.4.5.3. Prevalent cases of CKD by etiologies in Spain

6.4.5.4. Comorbidities associated with CKD in Spain

6.4.5.5. Dialysis Dependency in CKD in Spain

6.4.6. The United Kingdom

6.4.6.1. Diagnosed Prevalent cases of CKD in the United Kingdom

6.4.6.2. Prevalent cases of CKD by stage in the United Kingdom

6.4.6.3. Prevalent cases of CKD by etiologies in the United Kingdom

6.4.6.4. Comorbidities associated with CKD in the United Kingdom

6.4.6.5. Dialysis Dependency in CKD in the United Kingdom

6.5. Japan

6.5.1. Assumption and Rationale

6.5.2. Diagnosed Prevalent cases of CKD in Japan

6.5.3. Prevalent cases of CKD by stage in Japan

6.5.4. Prevalent cases of CKD by etiologies in Japan

6.5.5. Comorbidities associated with CKD in Japan

6.5.6. Dialysis Dependency in CKD in Japan

7. Treatment and Management

7.1. Biosimilars

7.2. Treatment guidelines for CKD

7.2.1. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline

7.2.2. NICE Guidelines

7.3. Case Study

7.3.1. Improving Outcomes for Patients with Chronic Kidney Disease

7.4. Patient Journey for CKD

8. Unmet Needs

9. Market Drivers

10. Market Barriers

11. Appendix

11.1. Report Methodology

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

Table 1: Summary of Chronic Kidney Disease (CKD) Market, Epidemiology, and Key Events (2017–2030)

Table 2: Total Prevalent Patient Population of CKD in 7MM (2017–2030)

Table 3: Diagnosed Prevalent Cases of CKD in the United States (2017-2030)

Table 4: Prevalent Cases of CKD by stage in the United States (2017-2030)

Table 5: Prevalent cases of CKD by etiologies in the United States (2017-2030)

Table 6: Comorbidities associated with CKD in the United States (2017-2030)

Table 7: Dialysis dependency in the United States (2017-2030)

Table 8: Diagnosed Prevalent Cases of CKD in Germany (2017-2030)

Table 9: Prevalent Cases of CKD by stage in Germany (2017-2030)

Table 10: Prevalent cases of CKD by etiologies in Germany (2017-2030)

Table 11: Comorbidities associated with CKD in Germany (2017-2030)

Table 12: Dialysis dependency in Germany (2017-2030)

Table 13: Diagnosed Prevalent Cases of CKD in France (2017-2030)

Table 14: Prevalent Cases of CKD by stage in France (2017-2030)

Table 15: Prevalent cases of CKD by etiologies in France (2017-2030)

Table 16: Comorbidities associated with CKD in France (2017-2030)

Table 17: Dialysis dependency in France (2017-2030)

Table 18: Diagnosed Prevalent Cases of CKD in Italy (2017-2030)

Table 19: Prevalent Cases of CKD by stage in Italy (2017-2030)

Table 20: Prevalent cases of CKD by etiologies in Italy (2017-2030)

Table 21: Comorbidities associated with CKD in Italy (2017-2030)

Table 22: Dialysis dependency in Italy (2017-2030)

Table 23: Diagnosed Prevalent Cases of CKD in Spain (2017-2030)

Table 24: Prevalent Cases of CKD by stage in Spain (2017-2030)

Table 25: Prevalent cases of CKD by etiologies in Spain (2017-2030)

Table 26: Comorbidities associated with CKD in Spain (2017-2030)

Table 27: Dialysis dependency in Spain (2017-2030)

Table 28: Diagnosed Prevalent Cases of CKD in the United Kingdom (2017-2030)

Table 29: Prevalent Cases of CKD by stage in the United Kingdom (2017-2030)

Table 30: Prevalent cases of CKD by etiologies in the United Kingdom (2017-2030)

Table 31: Comorbidities associated with CKD in the United Kingdom (2017-2030)

Table 32: Dialysis dependency in the United Kingdom (2017-2030)

Table 33: Diagnosed Prevalent Cases of CKD in Japan (2017-2030)

Table 34: Prevalent Cases of CKD by stage in Japan (2017-2030)

Table 35: Prevalent cases of CKD by etiologies in Japan (2017-2030)

Table 36: Comobidities associated with CKD in Japan (2017-2030)

Table 37: Dialysis dependency in Japan (2017-2030)



List of Figures

Figure 1: SWOT Analysis

Figure 2: Total Prevalent Patient Population of CKD in 7MM (2017–2030)

Figure 3: Diagnosed prevalent cases of CKD in the United States (2017-2030)

Figure 4: Prevalent Cases of CKD by stage in the United States (2017-2030)

Figure 5: Prevalent cases of CKD by etiologies in the United States (2017-2030)

Figure 6: Comorbidities associated with CKD in the United States (2017-2030)

Figure 7: Dialysis dependency in the United States (2017-2030)

Figure 8: Diagnosed prevalent cases of CKD in Germany (2017-2030)

Figure 9: Prevalent Cases of CKD by stage in Germany (2017-2030)

Figure 10: Prevalent cases of CKD by etiologies in the Germany (2017-2030)

Figure 11: Comorbidities associated with CKD Germany (2017-2030)

Figure 12: Dialysis dependency in Germany (2017-2030)

Figure 13: Diagnosed prevalent cases of CKD in the France (2017-2030)

Figure 14: Prevalent Cases of CKD by stage in France (2017-2030)

Figure15: Prevalent cases of CKD by etiologies in France (2017-2030)

Figure 16: Comorbidities associated with CKD in France (2017-2030)

Figure 17: Dialysis dependency in France (2017-2030)

Figure 18: Diagnosed prevalent cases of CKD in Italy (2017-2030)

Figure 19: Prevalent Cases of CKD by stage in Italy (2017-2030)

Figure 20: Prevalent cases of CKD by etiologies in Italy (2017-2030)

Figure 21: Comorbidities associated with CKD in Italy (2017-2030)

Figure 22: Dialysis dependency in Italy (2017-2030)

Figure 23: Diagnosed prevalent cases of CKD in Spain (2017-2030)

Figure 24: Prevalent Cases of CKD by stage in Spain (2017-2030)

Figure 25: Prevalent cases of CKD by etiologies in Spain (2017-2030)

Figure 26: Comorbidities associated with CKD in Spain (2017-2030)

Figure 27: Dialysis dependency in Spain (2017-2030)

Figure 28: Diagnosed prevalent cases of CKD in the United Kingdom (2017-2030)

Figure 29: Prevalent Cases of CKD by stage in the United Kingdom (2017-2030)

Figure 30: Prevalent cases of CKD by etiologies in the United Kingdom (2017-2030)

Figure 31: Comorbidities associated with CKD in the United Kingdom(2017-2030)

Figure 32: Dialysis dependency in the United Kingdom (2017-2030)

Figure 33: Diagnosed prevalent cases of CKD in Japan (2017-2030)

Figure 34: Prevalent Cases of CKD by stage in Japan (2017-2030)

Figure 35: Prevalent cases of CKD by etiologies in Japan (2017-2030)

Figure 36: Comorbidities associated with CKD in Japan (2017-2030)

Figure 37: Dialysis dependency in the Japan (2017-2030)

Figure 38: Steps in Manufacturing a Biologic Drug

Figure 39: Unmet Needs of Chronic Kidney Disease (CKD)

Figure 40: Market Drivers

Figure 41: Market Barriers

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[慢性腎臓病治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆